The auto-antigen repertoire in myasthenia gravis

References

• Gilhus NE. Autoimmune myasthenia gravis. Expert Rev Neurother. 2009; 9 3: 351–358.
   PubMed Web of Science ®Google Scholar
• Verschuuren JJ, Palace J, Gilhus NE. Clinical aspects of myasthenia explained. Autoimmunity. 2010; 43 5: 344–352.
   Google Scholar
• Engel AG, Lambert EH, Howard FM. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: Ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc. 1977; 52 5: 267–280.
   PubMed Web of Science ®Google Scholar
• Toyka KV, Drachman DB, Griffin DE, Pestronk A, Winkelstein JA, Fishbeck KH, Kao I. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med. 1977; 296 3: 125–131.
   Google Scholar
• Patrick J, Lindstrom J. Autoimmune response to acetylcholine receptor. Science. 1973; 180 88: 871–872.
   PubMed Web of Science ®Google Scholar
• Newsom-Davis J, Pinching AJ, Vincent A, Wilson SG. Function of circulating antibody to acetylcholine receptor in myasthenia gravis: Investigation by plasma exchange. Neurology. 1978; 28 3: 266–272.
   PubMedGoogle Scholar
• Chan KH, Lachance DH, Harper CM, Lennon VA. Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle Nerve. 2007; 36 5: 651–658.
   PubMed Web of Science ®Google Scholar
• Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001; 7 3: 365–368.
   PubMed Web of Science ®Google Scholar
• Gomez J, Van den Broeck J, Vrolix K, Janssen SP, Lemmens MA, van der Esch E, Duimel H, Frederik P, Molenaar PC, Martínez-Martínez P, De Baets MH, Losen M. Antibody effector mechanisms in myasthenia gravis—pathogenesis at the neuromuscular junction. Autoimmunity. 2010; 43 5: 353–370.
   Google Scholar
• Lavrnic D, Nikolic A, De Baets M, Verschuuren J, Verduyn W, Losen M, Stojanovic V, Stevic Z, Hajdukovic L, Apostolski S. Familial occurrence of autoimmune myasthenia gravis with different antibody specificity. Neurology. 2008; 70 21: 2011–2013.
   Google Scholar
• Evoli A, Batocchi AP, Zelano G, Uncini A, Palmisani MT, Tonali P. Familial autoimmune myasthenia gravis: Report of four families. J Neurol Neurosurg Psych. 1995; 58 6: 729–731.
   Google Scholar
• Provenzano C, Arancio O, Evoli A, Rocca B, Bartoccioni E, de Grandis D, Tonali P. Familial autoimmune myasthenia gravis with different pathogenetic antibodies. J Neurol Neurosurg Psych. 1988; 51 9: 1228–1230.
   Google Scholar
• Bergoffen J, Zmijewski CM, Fischbeck KH. Familial autoimmune myasthenia gravis. Neurology. 1994; 44 3 Pt 1: 551–554.
   Google Scholar
• Millar NS, Gotti C. Diversity of vertebrate nicotinic acetylcholine receptors. Neuropharmacology. 2009; 56 1: 237–246.
   PubMed Web of Science ®Google Scholar
• Popot JL, Changeux JP. Nicotinic receptor of acetylcholine: Structure of an oligomeric integral membrane protein. Physiol Rev. 1984; 64 4: 1162–1239.
   Web of Science ®Google Scholar
• Mishina M, Takai T, Imoto K, Noda M, Takahashi T, Numa S, Methfessel C, Sakmann B. Molecular distinction between fetal and adult forms of muscle acetylcholine receptor. Nature. 1986; 321 6068: 406–411.
   PubMed Web of Science ®Google Scholar
• Sine SM. The nicotinic receptor ligand binding domain. J Neurobiol. 2002; 53 4: 431–446.
   Google Scholar
• Noda M, Takahashi H, Tanabe T, Toyosato M, Furutani Y, Hirose T, Asai M, Inayama S, Miyata T, Numa S. Primary structure of alpha-subunit precursor of torpedo californica acetylcholine receptor deduced from cDNA sequence. Nature. 1982; 299 5886: 793–797.
   Google Scholar
• Sumikawa K, Houghton M, Smith JC, Bell L, Richards BM, Barnard EA. The molecular cloning and characterisation of cDNA coding for the alpha subunit of the acetylcholine receptor. Nucl Acids Res. 1982; 10 19: 5809–5822.
   Google Scholar
• Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology. 1976; 26 11: 1054–1059.
   PubMed Web of Science ®Google Scholar
• Lindstrom JM. Acetylcholine receptors and myasthenia. Muscle Nerve. 2000; 23 4: 453–477.
   Google Scholar
• Lefvert AK, Bergstrom K, Matell G, Osterman PO, Pirskanen R. Determination of acetylcholine receptor antibody in myasthenia gravis: Clinical usefulness and pathogenetic implications. J Neurol Neurosurg Psych. 1978; 41 5: 394–403.
   Google Scholar
• Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: Results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psych. 1985; 48 12: 1246–1252.
   PubMedGoogle Scholar
• Lindstrom J. An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis. Clin Immunol Immunopathol. 1977; 7 1: 36–43.
   Google Scholar
• Tzartos SJ, Lindstrom JM. Monoclonal antibodies used to probe acetylcholine receptor structure: Localization of the main immunogenic region and detection of similarities between subunits. Proc Natl Acad Sci USA. 1980; 77 2: 755–759.
   Google Scholar
• Mamalaki A, Tzartos SJ. Nicotinic acetylcholine receptor: Structure, function and main immunogenic region. Adv Neuroimmunol. 1994; 4 4: 339–354.
   Google Scholar
• Rodgaard A, Nielsen FC, Djurup R, Somnier F, Gammeltoft S. Acetylcholine receptor antibody in myasthenia gravis: Predominance of IgG subclasses 1 and 3. Clin Exp Immunol. 1987; 67 1: 82–88.
   PubMed Web of Science ®Google Scholar
• Heinemann S, Bevan S, Kullberg R, Lindstrom J, Rice J. Modulation of acetylcholine receptor by antibody against the receptor. Proc Natl Acad Sci USA. 1977; 74 7: 3090–3094.
   Google Scholar
• Loutrari H, Kokla A, Tzartos SJ. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor. Eur J Immunol. 1992; 22 9: 2449–2452.
   PubMed Web of Science ®Google Scholar
• Drachman DB, Angus CW, Adams RN, Michelson JD, Hoffman GJ. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N Engl J Med. 1978; 298 20: 1116–1122.
   Google Scholar
• Losen M, Martinez-Martinez P, Phernambucq M, Schuurman J, Parren PW, De Baets MH. Treatment of myasthenia gravis by preventing acetylcholine receptor modulation. Ann NY Acad Sci. 2008; 1132:174–179.
   PubMed Web of Science ®Google Scholar
• van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martinez-Martinez P, Vermeulen E, den Bleker TH, Wiegman L, Vink T, Aarden LA. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science. 2007; 317 5844: 1554–1557etal.
   PubMed Web of Science ®Google Scholar
• Chamberlain-Banoub J, Neal JW, Mizuno M, Harris CL, Morgan BP. Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats. Clin Exp Immunol. 2006; 146 2: 278–286.
   Google Scholar
• Martinez-Martinez P, Losen M, Duimel H, Frederik P, Spaans F, Molenaar P, Vincent A, De Baets MH. Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis. Am J Pathol. 2007; 170 2: 644–657.
   Google Scholar
• Ito H, Yoshimura T, Satoh A, Takino H, Tsujihata M, Nagataki S. Immunohistochemical study of utrophin and dystrophin at the motor end-plate in myasthenia gravis. Acta Neuropathol. 1996; 92 1: 14–18.
   Google Scholar
• Slater CR, Young C, Wood SJ, Bewick GS, Anderson LV, Baxter P, Fawcett PR, Roberts M, Jacobson L, Kuks J, Vincent A, Newsom-Davis J. Utrophin abundance is reduced at neuromuscular junctions of patients with both inherited and acquired acetylcholine receptor deficiencies. Brain. 1997; 120 Pt 9: 1513–1531.
   Google Scholar
• Losen M, Stassen MH, Martinez-Martinez P, Machiels BM, Duimel H, Frederik P, Veldman H, Wokke JH, Spaans F, Vincent A, De Baets MH. Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis. Brain. 2005; 128 Pt 10: 2327–2337.
   Google Scholar
• Martinez-Martinez P, Phernambucq M, Steinbusch L, Schaeffer L, Berrih-Aknin S, Duimel H, Frederik P, Molenaar P, De Baets MH, Losen M. Silencing rapsyn in vivo decreases acetylcholine receptors and augments sodium channels and secondary postsynaptic membrane folding. Neurobiol Dis. 2009; 35 1: 14–23.
   Google Scholar
• De Baets M, Stassen M, Losen M, Zhang X, Machiels B. Immunoregulation in experimental autoimmune myasthenia gravis—about T cells, antibodies, and endplates. Ann NY Acad Sci. 2003; 998:308–317.
   Google Scholar
• Almon RR, Andrew CG, Appel SH. Serum globulin in myasthenia gravis: Inhibition of alpha-bungarotoxin binding to acetylcholine receptors. Science. 1974; 186 4158: 55–57.
   Google Scholar
• Gomez CM, Richman DP. Anti-acetylcholine receptor antibodies directed against the alpha-bungarotoxin binding site induce a unique form of experimental myasthenia. Proc Natl Acad Sci USA. 1983; 80 13: 4089–4093.
   Google Scholar
• Lang B, Richardson G, Rees J, Vincent A, Newsom-Davis J. Plasma from myasthenia gravis patients reduces acetylcholine receptor agonist-induced Na+ flux into TE671 cell line. J Neuroimmunol. 1988; 19 1–2: 141–148.
   Google Scholar
• Wintzen AR, Plomp JJ, Molenaar PC, van Dijk JG, van Kempen GT, Vos RM, Wokke JH, Vincent A. Acquired slow-channel syndrome: A form of myasthenia gravis with prolonged open time of the acetylcholine receptor channel. Ann Neurol. 1998; 44 4: 657–664.
   PubMed Web of Science ®Google Scholar
• Alpert LI, Papatestas A, Kark A, Osserman RS, Osserman K. A histologic reappraisal of the thymus in myasthenia gravis. A correlative study of thymic pathology and response to thymectomy. Arch Pathol. 1971; 91 1: 55–61.
   Google Scholar
• Myking A, Skeie GO, Varhaug JE, Andersen KS, Gilhus NE, Aarli JA. The histomorphology of the thymus in late onset, non-thymoma myasthenia gravis. Euro J Neurol. 1998; 5:401–405.
   Web of Science ®Google Scholar
• Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol. 2002; 2 10: 797–804.
   PubMed Web of Science ®Google Scholar
• Romi F, Gilhus NE, Aarli JA. Myasthenia gravis: Clinical, immunological, and therapeutic advances. Acta Neurol Scand. 2005; 111 2: 134–141.
   PubMed Web of Science ®Google Scholar
• Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet. 2001; 357 9274: 2122–2128.
   PubMed Web of Science ®Google Scholar
• Scadding GK, Vincent A, Newsom-Davis J, Henry K. Acetylcholine receptor antibody synthesis by thymic lymphocytes: Correlation with thymic histology. Neurology. 1981; 31 8: 935–943.
   PubMed Web of Science ®Google Scholar
• Kuks JB, Oosterhuis HJ, Limburg PC, The TH. Anti-acetylcholine receptor antibodies decrease after thymectomy in patients with myasthenia gravis. Clinical Correlations. J Autoimmun. 1991; 4 2: 197–211.
   Google Scholar
• Le Panse R, Bismuth J, Cizeron-Clairac G, Weiss JM, Cufi P, Dartevelle P, Kerlero de Rosbo N, Berrih-Aknin S. Thymic remodeling associated with hyperplasia in myasthenia gravis. Autoimmunity. 2010; 43 5: 401–412.
   Google Scholar
• Andrews PI, Massey JM, Sanders DB. Acetylcholine receptor antibodies in juvenile myasthenia gravis. Neurology. 1993; 43 5: 977–982.
   Google Scholar
• Andrews PI, Massey JM, Howard JFJr, Sanders DB. Race, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis. Neurology. 1994; 44 7: 1208–1214.
   Google Scholar
• Chiu HC, Vincent A, Newsom-Davis J, Hsieh KH, Hung T. Myasthenia gravis: Population differences in disease expression and acetylcholine receptor antibody titers between Chinese and Caucasians. Neurology. 1987; 37 12: 1854–1857.
   Google Scholar
• Tindall RS. Humoral immunity in myasthenia gravis: Biochemical characterization of acquired antireceptor antibodies and clinical correlations. Ann Neurol. 1981; 10 5: 437–447.
   Google Scholar
• Tindall RS. Humoral immunity in myasthenia gravis: Clinical correlations of anti-receptor antibody avidity and titer. Ann NY Acad Sci. 1981; 377:316–331.
   PubMed Web of Science ®Google Scholar
• Demaine A, Willcox N, Janer M, Welsh K, Newsom-Davis J. Immunoglobulin heavy chain gene associations in myasthenia gravis: New evidence for disease heterogeneity. J Neurol. 1992; 239 1: 53–56.
   Google Scholar
• Oosterhuis HJ, Limburg PC, Hummel-Tappel E, The TH. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients. J Neurol Sci. 1983; 58 3: 371–385.
   PubMed Web of Science ®Google Scholar
• Vincent A. Newsom Davis J. Anti-acetylcholine receptor antibodies. J Neurol Neurosurg Psych. 1980; 43 7: 590–600.
   Google Scholar
• Newsom-Davis J, Vincent A. Combined plasma exchange and immunosuppression in myasthenia gravis. Lancet. 1979; 2 8144: 688.
   Google Scholar
• Janssen SP, Phernambucq M, Martinez-Martinez P, De Baets MH, Losen M. Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil. J Neuroimmunol. 2008; 201–202:111–120.
   Google Scholar
• Guyon T, Levasseur P, Truffault F, Cottin C, Gaud C, Berrih-Aknin S. Regulation of acetylcholine receptor alpha subunit variants in human myasthenia gravis. Quantification of steady-state levels of messenger RNA in muscle biopsy using the polymerase chain reaction. J Clin Invest. 1994; 94 1: 16–24.
   Google Scholar
• Moulian N, Wakkach A, Guyon T, Poea S, Aissaoui A, Levasseur P, Cohen-Kaminsky S, Berrih-Aknin S. Respective role of thymus and muscle in autoimmune myasthenia gravis. Ann NY Acad Sci. 1998; 841:397–406.
   PubMedGoogle Scholar
• Zhang B, Luo S, Wang Q, Suzuki T, Xiong WC, Mei L. LRP4 serves as a coreceptor of agrin. Neuron. 2008; 60 2: 285–297.
   Google Scholar
• Kim N, Stiegler AL, Cameron TO, Hallock PT, Gomez AM, Huang JH, Hubbard SR, Dustin ML, Burden SJ. Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell. 2008; 135 2: 334–342.
   PubMed Web of Science ®Google Scholar
• Glass DJ, Bowen DC, Stitt TN, Radziejewski C, Bruno J, Ryan TE, Gies DR, Shah S, Mattsson K, Burden SJ, DiStefano PS, Valenzuela DM, DeChiara TM, Yancopoulos GD. Agrin acts via a MuSK receptor complex. Cell. 1996; 85 4: 513–523.
   PubMed Web of Science ®Google Scholar
• Chevessier F, Faraut B, Ravel-Chapuis A, Richard P, Gaudon K, Bauche S, Prioleau C, Herbst R, Goillot E, Ioos C, Azulay JP, Attarian S, Leroy JP, Fournier E, Legay C, Schaeffer L, Koenig J, Fardeau M, Eymard B, Pouget J, Hantai D. MUSK, a new target for mutations causing congenital myasthenic syndrome. Hum Mol Genet. 2004; 13 24: 3229–3240.
   Google Scholar
• Chevessier F, Girard E, Molgo J, Bartling S, Koenig J, Hantai D, Witzemann V. A mouse model for congenital myasthenic syndrome due to MuSK mutations reveals defects in structure and function of neuromuscular junctions. Hum Mol Genet. 2008; 17 22: 3577–3595.
   Google Scholar
• McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, Newsom-Davis J, Vincent A. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol. 2004; 55 4: 580–584.
   PubMed Web of Science ®Google Scholar
• Yeh JH, Chen WH, Chiu HC, Vincent A. Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese. Neurology. 2004; 62 11: 2131–2132.
   Google Scholar
• Niks EH, Kuks JB, Verschuuren JJ. Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in The Netherlands. J Neurol Neurosurg Psychiatry. 2007; 78 4: 417–418.
   Google Scholar
• Zhou L, McConville J, Chaudhry V, Adams RN, Skolasky RL, Vincent A, Drachman DB. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve. 2004; 30 1: 55–60.
   Google Scholar
• Ohta K, Shigemoto K, Kubo S, Maruyama N, Abe Y, Ueda N, Ohta M. MuSK antibodies in AChR Ab-seropositive MG vs AChR Ab-seronegative MG. Neurology. 2004; 62 11: 2132–2133.
   PubMed Web of Science ®Google Scholar
• Padua L, Tonali P, Aprile I, Caliandro P, Bartoccioni E, Evoli A. Seronegative myasthenia gravis: Comparison of neurophysiological picture in MuSK+ and MuSK − patients. Eur J Neurol. 2006; 13 3: 273–276.
   Google Scholar
• Diaz-Manera J, Rojas-Garcia R, Gallardo E, Juarez C, Martinez-Domeno A, Martinez-Ramirez S, Dalmau J, Blesa R, Illa I. Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome. Nat Clin Pract Neurol. 2007; 3 7: 405–410.
   PubMedGoogle Scholar
• Jha S, Xu K, Maruta T, Oshima M, Mosier DR, Atassi MZ, Hoch W. Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J Neuroimmunol. 2006; 175 1–2: 107–117.
   Google Scholar
• Shigemoto K, Kubo S, Maruyama N, Hato N, Yamada H, Jie C, Kobayashi N, Mominoki K, Abe Y, Ueda N, Matsuda S. Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest. 2006; 116 4: 1016–1024.
   PubMed Web of Science ®Google Scholar
• Shigemoto K, Kubo S, Jie C, Hato N, Abe Y, Ueda N, Kobayashi N, Kameda K, Mominoki K, Miyazawa A, Ishigami A, Matsuda S, Maruyama N. Myasthenia gravis experimentally induced with muscle-specific kinase. Ann NY Acad Sci. 2008; 1132:93–98.
   Google Scholar
• ter Beek WP, Martínez-Martínez P, Losen M, de Baets MH, Wintzen AR, Verschuuren JJ, Niks EH, van Duinen SG, Vincent A, Molenaar PC. The effect of plasma from MuSK myasthenia patients on regenerating endplates. Am J Pathol. 2009; 175 4: 1536–1544.
   Google Scholar
• Zhu D, Yang Z, Luo Z, Luo S, Xiong WC, Mei L. Muscle-specific receptor tyrosine kinase endocytosis in acetylcholine receptor clustering in response to agrin. J Neurosci. 2008; 28 7: 1688–1696.
   Google Scholar
• Lavrnic D, Losen M, Vujic A, De Baets M, Hajdukovic LJ, Stojanovic V, Trikic R, Djukic P, Apostolski S. The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psych. 2005; 76 8: 1099–1102.
   Google Scholar
• Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, Batocchi AP, Marino M, Bartoccioni E. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003; 126 Pt 10: 2304–2311.
   Google Scholar
• Bartoccioni E, Scuderi F, Minicuci GM, Marino M, Ciaraffa F, Evoli A. Anti-MuSK antibodies: Correlation with myasthenia gravis severity. Neurology. 2006; 67 3: 505–507.
   PubMed Web of Science ®Google Scholar
• Niks EH, van Leeuwen Y, Leite MI, Dekker FW, Wintzen AR, Wirtz PW, Vincent A, van Tol MJ, Jol-van der Zijde CM, Verschuuren JJ. Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. J Neuroimmunol. 2008; 195 1–2: 151–156.
   PubMed Web of Science ®Google Scholar
• Lauriola L, Ranelletti F, Maggiano N, Guerriero M, Punzi C, Marsili F, Bartoccioni E, Evoli A. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology. 2005; 64 3: 536–538.
   PubMedGoogle Scholar
• Leite MI, Strobel P, Jones M, Micklem K, Moritz R, Gold R, Niks EH, Berrih-Aknin S, Scaravilli F, Canelhas A, Marx A, Newsom-Davis J, Willcox N, Vincent A. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol. 2005; 57 3: 444–448.
   PubMed Web of Science ®Google Scholar
• Evoli A, Batocchi AP, Lo Monaco M, Servidei S, Padua L, Majolini L, Tonali P. Clinical heterogeneity of seronegative myasthenia gravis. Neuromuscul Disord. 1996; 6 3: 155–161.
   Google Scholar
• Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D, Willcox N, Vincent A. IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis. Brain. 2008; 131 Pt 7: 1940–1952.
   Google Scholar
• Leite MI, Waters P, Vincent A. Diagnostic use of auto-antibodies in myasthenia gravis. Autoimmunity. 2010; 43 5: 371–379.
   Google Scholar
• Farrugia ME, Bonifati DM, Clover L, Cossins J, Beeson D, Vincent A. Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures. J Neuroimmunol. 2007; 185 1–2: 136–144.
   Google Scholar
• Hayashi A, Shiono H, Ohta M, Ohta K, Okumura M, Sawa Y. Heterogeneity of immunopathological features of AChR/MuSK autoantibody-negative myasthenia gravis. J Neuroimmunol. 2007; 189 1–2: 163–168.
   Google Scholar
• Engel AG, Lambert EH, Mulder DM, Torres CF, Sahashi K, Bertorini TE, Whitaker JN. A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel. Ann Neurol. 1982; 11 6: 553–569.
   Google Scholar
• Gomez CM, Maselli R, Gammack J, Lasalde J, Tamamizu S, Cornblath DR, Lehar M, McNamee M, Kuncl RW. A beta-subunit mutation in the acetylcholine receptor channel gate causes severe slow-channel syndrome. Ann Neurol. 1996; 39 6: 712–723.
   Google Scholar
• Ohno K, Hutchinson DO, Milone M, Brengman JM, Bouzat C, Sine SM, Engel AG. Congenital myasthenic syndrome caused by prolonged acetylcholine receptor channel openings due to a mutation in the M2 domain of the epsilon subunit. Proc Natl Acad Sci USA. 1995; 92 3: 758–762.
   Google Scholar
• Oosterhuis HJ, Newsom-Davis J, Wokke JH, Molenaar PC, Weerden TV, Oen BS, Jennekens FG, Veldman H, Vincent A, Wray DW, . The slow channel syndrome. Two new cases. Brain. 1987; 110 Pt 4: 1061–1079.
   Google Scholar
• Sine SM, Ohno K, Bouzat C, Auerbach A, Milone M, Pruitt JN, Engel AG. Mutation of the acetylcholine receptor alpha subunit causes a slow-channel myasthenic syndrome by enhancing agonist binding affinity. Neuron. 1995; 15 1: 229–239.
   Google Scholar
• Beeson D, Jacobson L, Newsom-Davis J, Vincent A. A transfected human muscle cell line expressing the adult subtype of the human muscle acetylcholine receptor for diagnostic assays in myasthenia gravis. Neurology. 1996; 47 6: 1552–1555.
   PubMed Web of Science ®Google Scholar
• Lambert EH, Elmqvist D. Quantal components of end-plate potentials in the myasthenic syndrome. Ann NY Acad Sci. 1971; 183:183–199.
   PubMed Web of Science ®Google Scholar
• Lennon VA, Kryzer TJ, Griesmann GE, O'Suilleabhain PE, Windebank AJ, Woppmann A, Miljanich GP, Lambert EH. Calcium-channel antibodies in the Lambert–Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995; 332 22: 1467–1474.
   PubMed Web of Science ®Google Scholar
• Cull-Candy SG, Miledi R, Trautmann A, Uchitel OD. On the release of transmitter at normal, myasthenia gravis and myasthenic syndrome affected human end-plates. J Physiol. 1980; 299:621–638.
   Google Scholar
• Molenaar PC, Newsom-Davis J, Polak RL, Vincent A. Eaton–Lambert syndrome: Acetylcholine and choline acetyltransferase in skeletal muscle. Neurology. 1982; 32 9: 1061–1065.
   Google Scholar
• Engel AG, Nagel A, Fukuoka T, Fukunaga H, Osame M, Lang B, Newsom-Davis J, Vincent A, Wray DW, Peers C. Motor nerve terminal calcium channels in Lambert–Eaton myasthenic syndrome. Morphologic evidence for depletion and that the depletion is mediated by autoantibodies. Ann NY Acad Sci. 1989; 560:278–290.
   Google Scholar
• Fukunaga H, Engel AG, Lang B, Newsom-Davis J, Vincent A. Passive transfer of Lambert–Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci USA. 1983; 80 24: 7636–7640.
   Google Scholar
• Vincent A, Lang B, Newsom-Davis J. Autoimmunity to the voltage-gated calcium channel underlies the Lambert–Eaton myasthenic syndrome, a paraneoplastic disorder. Trends Neurosci. 1989; 12 12: 496–502.
   Google Scholar
• Wirtz PW, Sotodeh M, Nijnuis M, Van Doorn PA, Van Engelen BG, Hintzen RQ, De Kort PL, Kuks JB, Twijnstra A, De Visser M, Wokke JH, Wintzen AR, Verschuuren JJ. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert–Eaton myasthenic syndrome. J Neurol Neurosurg Psych. 2002; 73 6: 766–768.
   Google Scholar
• Strauss AJL, Seegal BC, Hsu KC, Burkholder PM, Nastuk WL, Osserman KE. Immunofluorescence demonstration of a muscle binding, complement-fixing serum globulin fraction in mysthenia gravis. Proc Soc Exper Biol Med. 1960; 105:184.
   Web of Science ®Google Scholar
• Strauss AJ, Kemp PGJr. Serum autoantibodies in myasthenia gravis and thymoma: Selective affinity for I-bands of striated muscle as a guide to identification of antigen(s). J Immunol. 1967; 99 5: 945–953.
   Google Scholar
• Marx A, Willcox N, Leite MI, Chuang W, Schalke B, Nix W, Ströbel P. Thymoma and paraneoplastic myasthenia gravis. Autoimmunity. 2010; 43 5: 413–427.
   Google Scholar
• Wang K, McClure J, Tu A. Titin: Major myofibrillar components of striated muscle. Proc Natl Acad Sci USA. 1979; 76 8: 3698–3702.
   PubMed Web of Science ®Google Scholar
• Gautel M, Lakey A, Barlow DP, Holmes Z, Scales S, Leonard K, Labeit S, Mygland A, Gilhus NE, Aarli JA. Titin antibodies in myasthenia gravis: Identification of a major immunogenic region of titin. Neurology. 1993; 43 8: 1581–1585.
   PubMed Web of Science ®Google Scholar
• Lubke E, Freiburg A, Skeie GO, Kolmerer B, Labeit S, Aarli JA, Gilhus NE, Wollmann R, Wussling M, Ruegg JC, Linke WA. Striational autoantibodies in myasthenia gravis patients recognize I-band titin epitopes. J Neuroimmunol. 1998; 81 1–2: 98–108.
   Google Scholar
• Buckley C, Newsom-Davis J, Willcox N, Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?. Neurology. 2001; 57 9: 1579–1582.
   PubMed Web of Science ®Google Scholar
• Romi F, Skeie GO, Aarli JA, Gilhus NE. Muscle autoantibodies in subgroups of myasthenia gravis patients. J Neurol. 2000; 247 5: 369–375.
   PubMed Web of Science ®Google Scholar
• Aarli JA, Stefansson K, Marton LS, Wollmann RL. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin Exp Immunol. 1990; 82 2: 284–288.
   PubMed Web of Science ®Google Scholar
• Romi F, Bo L, Skeie GO, Myking A, Aarli JA, Gilhus NE. Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules. J Neuroimmunol. 2002; 128 1–2: 82–89.
   PubMed Web of Science ®Google Scholar
• Skeie GO, Freiburg A, Kolmerer B, Labeit S, Aarli JA, Appiah-Boadu S, Gilhus NE. Titin transcripts in thymomas. J Autoimmun. 1997; 10 6: 551–557.
   Google Scholar
• Romi F, Skeie GO, Aarli JA, Gilhus NE. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. Arch Neurol. 2000; 57 11: 1596–1600.
   PubMedGoogle Scholar
• Romi F, Skeie GO, Vedeler C, Aarli JA, Zorzato F, Gilhus NE. Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis. A study of IgG subclasses and clinical correlations. J Neuroimmunol. 2000; 111 1–2: 169–176.
   PubMed Web of Science ®Google Scholar
• Romi F, Gilhus NE, Varhaug JE, Myking A, Skeie GO, Aarli JA. Thymectomy and anti-muscle autoantibodies in late-onset myasthenia gravis. Eur J Neurol. 2002; 9 1: 55–61.
   Google Scholar
• Takeshima H, Iino M, Takekura H, Nishi M, Kuno J, Minowa O, Takano H, Noda T. Excitation–contraction uncoupling and muscular degeneration in mice lacking functional skeletal muscle ryanodine-receptor gene. Nature. 1994; 369 6481: 556–559.
   Google Scholar
• Williams AJ. Ion conduction and discrimination in the sarcoplasmic reticulum ryanodine receptor/calcium-release channel. J Muscle Res Cell Motil. 1992; 13 1: 7–26.
   Google Scholar
• Skeie GO, Mygland A, Treves S, Gilhus NE, Aarli JA, Zorzato F. Ryanodine receptor antibodies in myasthenia gravis: Epitope mapping and effect on calcium release in vitro. Muscle Nerve. 2003; 27 1: 81–89.
   PubMed Web of Science ®Google Scholar
• Takamori M, Motomura M, Kawaguchi N, Nemoto Y, Hattori T, Yoshikawa H, Otsuka K. Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis. Neurology. 2004; 62 10: 1894–1896.
   Google Scholar
• Skeie GO, Lunde PK, Sejersted OM, Mygland A, Aarli JA, Gilhus NE. Myasthenia gravis-associated ryanodine receptor antibodies inhibit binding of ryanodine to sarcoplasmic reticulum. Ann NY Acad Sci. 1998; 841:530–533.
   Google Scholar
• Mygland A, Tysnes OB, Matre R, Volpe P, Aarli JA, Gilhus NE. Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma. Ann Neurol. 1992; 32 4: 589–591.
   PubMed Web of Science ®Google Scholar
• Mygland A, Tysnes OB, Aarli JA, Flood PR, Gilhus NE. Myasthenia gravis patients with a thymoma have antibodies against a high molecular weight protein in sarcoplasmic reticulum. J Neuroimmunol. 1992; 37 1–2: 1–7.
   Google Scholar
• Mygland A, Tysnes OB, Matre R, Aarli JA, Gilhus NE. Anti-cardiac ryanodine receptor antibodies in thymoma-associated myasthenia gravis. Autoimmunity. 1994; 17 4: 327–331.
   PubMed Web of Science ®Google Scholar
• Romi F, Aarli JA, Gilhus NE. Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features. Eur J Neurol. 2007; 14 6: 617–620.
   PubMed Web of Science ®Google Scholar
• Skeie GO, Lunde PK, Sejersted OM, Mygland A, Aarli JA, Gilhus NE. Myasthenia gravis sera containing antiryanodine receptor antibodies inhibit binding of [3H]-ryanodine to sarcoplasmic reticulum. Muscle Nerve. 1998; 21 3: 329–335.
   Google Scholar
• Mygland A, Tysnes OB, Aarli JA, Matre R, Gilhus NE. IgG subclass distribution of ryanodine receptor autoantibodies in patients with myasthenia gravis and thymoma. J Autoimmun. 1993; 6 4: 507–515.
   Google Scholar
• Iwasa K, Komai K, Takamori M. Spontaneous thymoma rat as a model for myasthenic weakness caused by anti-ryanodine receptor antibodies. Muscle Nerve. 1998; 21 12: 1655–1660.
   Google Scholar
• Maruta T, Yoshikawa H, Fukasawa S, Umeshita S, Inaoka Y, Edahiro S, Kado H, Motozaki Y, Iwasa K, Yamada M. Autoantibody to dihydropyridine receptor in myasthenia gravis. J Neuroimmunol. 2009; 208 1–2: 125–129.
   Google Scholar
• Takamori M. Autoantibodies against TRPC3 and ryanodine receptor in myasthenia gravis. J Neuroimmunol. 2008; 200 1–2: 142–144.
   Google Scholar
• Williams CL, Lennon VA. Thymic B lymphocyte clones from patients with myasthenia gravis secrete monoclonal striational autoantibodies reacting with myosin, alpha actinin, or actin. J Exp Med. 1986; 164 4: 1043–1059.
   PubMed Web of Science ®Google Scholar
• Mohan S, Barohn RJ, Jackson CE, Krolick KA. Evaluation of myosin-reactive antibodies from a panel of myasthenia gravis patients. Clin Immunol Immunopathol. 1994; 70 3: 266–273.
   PubMedGoogle Scholar
• Takaya M, Kawahara S, Namba T, Grob D. Antibodies against myofibrillar proteins in myasthenia gravis patients. Tokai J Exp Clin Med. 1992; 17 1: 35–39.
   Google Scholar
• Ohta M, Ohta K, Itoh N, Kurobe M, Hayashi K, Nishitani H. Anti-skeletal muscle antibodies in the sera from myasthenic patients with thymoma: Identification of anti-myosin, actomyosin, actin, and alpha-actinin antibodies by a solid-phase radioimmunoassay and a Western blotting analysis. Clin Chim Acta. 1990; 187 3: 255–264.
   Google Scholar
• Yamamoto T, Sato T, Sugita H. Antifilamin, antivinculin, and antitropomyosin antibodies in myasthenia gravis. Neurology. 1987; 37 8: 1329–1333.
   Google Scholar
• Lin H. [ELISA for detection of anti-filamin antibody in sera from patient with myasthenia gravis]. Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1992; 25 5: 281–283, 316–317.
   Google Scholar
• Gautam M, Noakes PG, Mudd J, Nichol M, Chu GC, Sanes JR, Merlie JP. Failure of postsynaptic specialization to develop at neuromuscular junctions of rapsyn-deficient mice. Nature. 1995; 377 6546: 232–236.
   Google Scholar
• Agius MA, Zhu S, Kirvan CA, Schafer AL, Lin MY, Fairclough RH, Oger JJ, Aziz T, Aarli JA. Rapsyn antibodies in myasthenia gravis. Ann NY Acad Sci. 1998; 841:516–521.
   PubMed Web of Science ®Google Scholar
• Agius MA, Zhu S, Aarli JA. Antirapsyn antibodies occur commonly in patients with lupus. Ann NY Acad Sci. 1998; 841:525–526.
   PubMed Web of Science ®Google Scholar
• Phillips TM, Manz HJ, Smith FA, Jaffe HA, Cohan SL. The detection of anti-cholinesterase antibodies in myasthenia gravis. Ann NY Acad Sci. 1981; 377:360–371.
   PubMed Web of Science ®Google Scholar
• Mappouras DG, Philippou G, Haralambous S, Tzartos SJ, Balafas A, Souvatzoglou A, Lymberi P. Antibodies to acetylcholinesterase cross-reacting with thyroglobulin in myasthenia gravis and Graves's disease. Clin Exp Immunol. 1995; 100 2: 336–343.
   Google Scholar
• Tang J, Yuan J, Hao H. Anti-acetylcholinesterase antibody in myasthenic syndrome. Chin Med J (Engl). 1997; 110 9: 698–700.
   Google Scholar
• Geen J, Howells RC, Ludgate M, Hullin DA, Hogg SI. The prevalence of anti-acetylcholinesterase antibodies in autoimmune disease. Autoimmunity. 2004; 37 8: 579–585.
   PubMed Web of Science ®Google Scholar
• Brimijoin S, Lennon VA. Autoimmune preganglionic sympathectomy induced by acetylcholinesterase antibodies. Proc Natl Acad Sci USA. 1990; 87 24: 9630–9634.
   Google Scholar
• Lu CZ, Link H, Mo XA, Xiao BG, Zhang YL, Qin Z. Anti-presynaptic membrane receptor antibodies in myasthenia gravis. J Neurol Sci. 1991; 102 1: 39–45.
   Google Scholar
• Xiao BG, Lu CZ, Hojeberg B, Link H. Immunological specificity and cross-reactivity of anti-acetylcholine receptor and anti-presynaptic membrane receptor antibodies in myasthenia gravis. J Neurol Sci. 1991; 105 1: 118–123.
   Google Scholar
• Lu CZ, Lu L, Hao ZS, Xia DG, Qain J, Arnason BG. Antibody-secreting cells to acetylcholine receptor and to presynaptic membrane receptor in seronegative myasthenia gravis. J Neuroimmunol. 1993; 43 1–2: 145–149.
   Google Scholar
• Link H, Sun JB, Lu CZ, Xiao BG, Fredrikson S, Hojeberg B, Olsson T. Myasthenia gravis: T and B-cell reactivities to the beta-bungarotoxin binding protein presynaptic membrane receptor. J Neurol Sci. 1992; 109 2: 173–181.
   Google Scholar
• Xu K, Shu XQ, Zhuo XL, Lu CZ. Presynaptic changes of neuromuscular transmission in mice induced by passive transfer of plasma with anti-presynaptic membrane receptor antibodies from a patient with myasthenia gravis. J Peripher Nerv Syst. 1998; 3 2: 103–109.
   Google Scholar
• Shillito P, Molenaar PC, Vincent A, Leys K, Zheng W, van den Berg RJ, Plomp JJ, van Kempen GT, Chauplannaz G, Wintzen AR, . Acquired neuromyotonia: Evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann Neurol. 1995; 38 5: 714–722.
   Google Scholar
• Hart IK, Waters C, Vincent A, Newland C, Beeson D, Pongs O, Morris C, Newsom-Davis J. Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol. 1997; 41 2: 238–246.
   Google Scholar
• Mygland A, Vincent A, Newsom-Davis J, Kaminski H, Zorzato F, Agius M, Gilhus NE, Aarli JA. Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia. Arch Neurol. 2000; 57 4: 527–531.
   Google Scholar
• Suzuki S, Satoh T, Yasuoka H, Hamaguchi Y, Tanaka K, Kawakami Y, Suzuki N, Kuwana M. Novel autoantibodies to a voltage-gated potassium channel Kv1.4 in a severe form of myasthenia gravis. J Neuroimmunol. 2005; 170 1–2: 141–149.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Utsugisawa K, Nagane Y, Satoh T, Terayama Y, Suzuki N, Kuwana M. Classification of myasthenia gravis based on autoantibody status. Arch Neurol. 2007; 64 8: 1121–1124.
   Google Scholar
• Toth C, McDonald D, Oger J, Brownell K. Acetylcholine receptor antibodies in myasthenia gravis are associated with greater risk of diabetes and thyroid disease. Acta Neurol Scand. 2006; 114 2: 124–132.
   Google Scholar
• Cojocaru IM, Cojocaru M, Musuroi C. Study of anti-striational and anti-thyroid antibodies in patients with myasthenia gravis. Rom J Intern Med. 2000; 38–39:111–120.
   Google Scholar
• Sagar HJ, Gelsthorpe K, Milford-Ward A, Davies-Jones GA. Clinical and immunological associations in myasthenia gravis. 1: Autoantibodies. J Neurol Neurosurg Psych. 1980; 43 11: 967–970.
   Google Scholar
• Kiessling WR, Pflughaupt KW, Ricker K, Haubitz I, Mertens HG. Thyroid function and circulating antithyroid antibodies in myasthenia gravis. Neurology. 1981; 31 6: 771–774.
   Google Scholar
• Weissel M, Mayr N, Zeitlhofer J. Clinical significance of autoimmune thyroid disease in myasthenia gravis. Exp Clin Endocrinol Diabetes. 2000; 108 1: 63–65.
   Google Scholar
• Nakamura H, Usa T, Motomura M, Ichikawa T, Nakao K, Kawasaki E, Tanaka M, Ishikawa K, Eguchi K. Prevalence of interrelated autoantibodies in thyroid diseases and autoimmune disorders. J Endocrinol Invest. 2008; 31 10: 861–865.
   Google Scholar
• Kiessling WR, Finke R, Kotulla P, Schleusener H. Circulating TSH-binding inhibiting immunoglobulins in myasthenia gravis. Acta Endocrinol (Copenh). 1982; 101 1: 41–46.
   Google Scholar
• White RG, Marshall AH. The autoimmune response in myasthenia gravis. Lancet. 1962; 2 7247: 120–123.
   Google Scholar
• Shoenfeld Y, Ben-Yehuda O, Messinger Y, Bentwitch Z, Rauch J, Isenberg DI, Gadoth N. Autoimmune diseases other than lupus share common anti-DNA idiotypes. Immunol Lett. 1988; 17 3: 285–291.
   Google Scholar
• Oosterhuis HJ, Feltkamp TE, van Rossum AL, van den Berg-Loonen PM, Nijenhuis LE. HL-A antigens, autoantibody production, and associated diseases in thymoma patients, with and without myasthenia gravis. Ann NY Acad Sci. 1976; 274:468–474.
   Google Scholar
• Sthoeger Z, Neiman A, Elbirt D, Zinger H, Magen E, Burstein R, Eitan S, Abarbanel J, Mozes E. High prevalence of systemic lupus erythematosus in 78 myasthenia gravis patients: A clinical and serologic study. Am J Med Sci. 2006; 331 1: 4–9.
   PubMed Web of Science ®Google Scholar
• Colaco CB, Scadding GK, Lockhart S. Anti-cardiolipin antibodies in neurological disorders: Cross-reaction with anti-single stranded DNA activity. Clin Exp Immunol. 1987; 68 2: 313–319.
   Google Scholar
• Warlow R, Garlepp M, Dawkins R. Extractable nuclear antigen autoantibodies and their association with other autoantibodies and thymoma in myasthenia gravis. J Neuroimmunol. 1985; 8 2–3: 185–197.
   Google Scholar
• Kinoshita I, Motomura M, Nagasato K, Ichinose K, Ohishi K, Takeo G, Satoh A, Nakamura T, Yoshimura T, Tsujihata M, Nagataki S. Antiphospholipid antibodies in patients with myastenia gravis. Acta Med Nagasaki. 1994; 39:41–44.
   Google Scholar
• Sanmarco M, Bernard D. Studies of IgG-class anticardiolipin antibodies in myasthenia gravis. Autoimmunity. 1994; 18 1: 57–63.
   PubMed Web of Science ®Google Scholar
• Garcia N, Santafe MM, Salon I, Lanuza MA, Tomas J. Expression of muscarinic acetylcholine receptors (M1-, M2-, M3- and M4-type) in the neuromuscular junction of the newborn and adult rat. Histol Histopathol. 2005; 20 3: 733–743.
   Google Scholar
• Takamori M, Motomura M, Fukudome T, Yoshikawa H. Autoantibodies against M1 muscarinic acetylcholine receptor in myasthenic disorders. Eur J Neurol. 2007; 14 11: 1230–1235.
   Google Scholar
• Plomp JJ, Van Kempen GT, De Baets MB, Graus YM, Kuks JB, Molenaar PC. Acetylcholine release in myasthenia gravis: Regulation at single end-plate level. Ann Neurol. 1995; 37 5: 627–636.
   Google Scholar
• Gotti C, Moretti M, Mantegazza R, Fornasari D, Tsouloufis T, Clementi F. Anti-neuronal nicotinic receptor antibodies in MG patients with thymoma. J Neuroimmunol. 2001; 113 1: 142–145.
   Google Scholar
• Balestra B, Moretti M, Longhi R, Mantegazza R, Clementi F, Gotti C. Antibodies against neuronal nicotinic receptor subtypes in neurological disorders. J Neuroimmunol. 2000; 102 1: 89–97.
   PubMed Web of Science ®Google Scholar
• Vernino S, Sandroni P, Singer W, Low PA. Invited article: Autonomic ganglia: Target and novel therapeutic tool. Neurology. 2008; 70 20: 1926–1932.
   PubMed Web of Science ®Google Scholar
• Lindstrom J. The Structure of nAChRs. In: Clementi F, Fornasari D, Gotti C. editors. Neuronal nicotinic receptors, Hand book of experimental pharmacology. Volume 144 Berlin: Springer-Verlag; 2000 101–147.
   Google Scholar
• Mihovilovic M, Roses AD. Expression of alpha-3, alpha-5, and beta-4 neuronal acetylcholine receptor subunit transcripts in normal and myasthenia gravis thymus. Identification of thymocytes expressing the alpha-3 transcripts. J Immunol. 1993; 151 11: 6517–6524.
   Google Scholar
• Eng H, Magnusson Y, Matell G, Lefvert AK, Saponja R, Hoebeke J. Beta 2-adrenergic receptor antibodies in myasthenia gravis. J Autoimmun. 1992; 5 2: 213–227.
   Google Scholar
• Xu BY, Pirskanen R, Lefvert AK. Antibodies against beta1 and beta2 adrenergic receptors in myasthenia gravis. J Neuroimmunol. 1998; 91 1–2: 82–88.
   Google Scholar
• Yi Q, He W, Matell G, Pirskanen R, Magnusson Y, Eng H, Lefvert AK. T and B lymphocytes reacting with the extracellular loop of the beta 2-adrenergic receptor (beta 2AR) are present in the peripheral blood of patients with myasthenia gravis. Clin Exp Immunol. 1996; 103 1: 133–140.
   PubMed Web of Science ®Google Scholar
• Magnusson Y, Marullo S, Hoyer S, Waagstein F, Andersson B, Vahlne A, Guillet JG, Strosberg AD, Hjalmarson A, Hoebeke J. Mapping of a functional autoimmune epitope on the beta 1-adrenergic receptor in patients with idiopathic dilated cardiomyopathy. J Clin Invest. 1990; 86 5: 1658–1663.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Uchida K, Nakagaki K, Kanazawa H, Trapnell BC, Hoshino Y, Kagamu H, Yoshizawa H, Keicho N, Goto H, Nakata K. Anti-cytokine autoantibodies are ubiquitous in healthy individuals. FEBS Lett. 2007; 581 10: 2017–2021.
   PubMed Web of Science ®Google Scholar
• Meager A, Wadhwa M, Bird C, Dilger P, Thorpe R, Newsom-Davis J, Willcox N. Spontaneously occurring neutralizing antibodies against granulocyte-macrophage colony-stimulating factor in patients with autoimmune disease. Immunology. 1999; 97 3: 526–532.
   PubMed Web of Science ®Google Scholar
• Meager A, Wadhwa M, Dilger P, Bird C, Thorpe R, Newsom-Davis J, Willcox N. Anti-cytokine autoantibodies in autoimmunity: Preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol. 2003; 132 1: 128–136.
   PubMed Web of Science ®Google Scholar
• Yoshikawa H, Sato K, Edahiro S, Furukawa Y, Maruta T, Iwasa K, Watanabe H, Takaoka S, Suzuki Y, Takamori M, Yamada M. Elevation of IL-12 p40 and its antibody in myasthenia gravis with thymoma. J Neuroimmunol. 2006; 175 1–2: 169–175.
   Google Scholar
• Meager A, Vincent A, Newsom-Davis J, Willcox N. Spontaneous neutralising antibodies to interferon–alpha and interleukin-12 in thymoma-associated autoimmune disease. Lancet. 1997; 350 9091: 1596–1597.
   Google Scholar
• Shiono H, Wong YL, Matthews I, Liu JL, Zhang W, Sims G, Meager A, Beeson D, Vincent A, Willcox N. Spontaneous production of anti-IFN-alpha and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor. Int Immunol. 2003; 15 8: 903–913.
   Google Scholar
• Wildbaum G, Nahir MA, Karin N. Beneficial autoimmunity to proinflammatory mediators restrains the consequences of self-destructive immunity. Immunity. 2003; 19 5: 679–688.
   PubMed Web of Science ®Google Scholar
• Hartl FU. Molecular chaperones in cellular protein folding. Nature. 1996; 381 6583: 571–579.
   PubMed Web of Science ®Google Scholar
• Astarloa R, Martinez Castrillo JC. Humoral response to the human heat shock 60 kDa protein in myasthenia gravis. J Neurol Sci. 1996; 135 2: 182–183.
   PubMed Web of Science ®Google Scholar
• Munakata S, Chen M, Aosai F, Kawaguchi N, Nemoto Y, Norose K, Hattori T, Yano A. The clinical significance of anti-heat shock cognate protein 71 antibody in myasthenia gravis. J Clin Neurosci. 2008; 15 2: 158–165.
   Google Scholar
• Minota S, Cameron B, Welch WJ, Winfield JB. Autoantibodies to the constitutive 73-kD member of the hsp70 family of heat shock proteins in systemic lupus erythematosus. J Exp Med. 1988; 168 4: 1475–1480.
   Google Scholar
• Gao YL, Raine CS, Brosnan CF. Humoral response to hsp 65 in multiple sclerosis and other neurologic conditions. Neurology. 1994; 44 5: 941–946.
   Google Scholar
• Hayem G, De Bandt M, Palazzo E, Roux S, Combe B, Eliaou JF, Sany J, Kahn MF, Meyer O. Anti-heat shock protein 70 kDa and 90 kDa antibodies in serum of patients with rheumatoid arthritis. Ann Rheum Dis. 1999; 58 5: 291–296.
   PubMed Web of Science ®Google Scholar
• Tuzun E, Saini SS, Ghosh S, Rowin J, Meriggioli MN, Christadoss P. Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis. Neuromuscul Disord. 2006; 16 2: 137–143.
   PubMed Web of Science ®Google Scholar
• Leone G, Breda M, Accorra F, Bizzi B. Platelet antibody determination by platelet factor 3 assay (comparison with radiolabelled serotonin release and platelet aggregometry). Ric Clin Lab. 1978; 8 3: 141–147.
   Google Scholar
• Okada S, Saito E, Oshima H, Kinoshita M. Autoantibody to growth hormone in a patient with myasthenia gravis. J Endocrinol. 1990; 127 3: 533–538.
   Google Scholar
• Muller KM. Anti-neuroblastoma antibodies in myasthenia gravis: Clinical and immunological correlations. J Neurol Sci. 1989; 93 2–3: 263–275.
   Google Scholar
• Muller KM, Andersson LC. Antibodies against human neuroblastoma cells in the sera of patients with myasthenia gravis. J Neuroimmunol. 1984; 7 2–3: 97–105.
   Google Scholar
• Muller KM, Nykyri E, Andersson LC. Effect of thymectomy and immunosuppressive therapy on anti-neuroblastoma antibody levels in patients with myasthenia gravis. Acta Neurol Scand. 1991; 83 5: 336–342.
   Google Scholar
• Safar D, Aime C, Cohen-Kaminsky S, Berrih-Aknin S. Antibodies to thymic epithelial cells in myasthenia gravis. J Neuroimmunol. 1991; 35 1–3: 101–110.
   Google Scholar
• Konishi T, Ohta K, Shigemoto K, Ohta M. Anti-alkaline phosphatase antibody positive myasthenia gravis. J Neurol Sci. 2007; 263 1–2: 89–93.
   Google Scholar
• Hanna AN, Waldman WJ, Lott JA, Koesters SC, Hughes AM, Thornton DJ. Increased alkaline phosphatase isoforms in autoimmune diseases. Clin Chem. 1997; 43 8 Pt 1: 1357–1364.
   Google Scholar
• Gordon T, Grove B, Loftus JC, O'Toole T, McMillan R, Lindstrom J, Ginsberg MH. Molecular cloning and preliminary characterization of a novel cytoplasmic antigen recognized by myasthenia gravis sera. J Clin Invest. 1992; 90 3: 992–999.
   Google Scholar
• Sasaki H, Kunimatsu M, Fujii Y, Yamakawa Y, Fukai I, Kiriyama M, Nonaka M, Sasaki M. Autoantibody to gravin is expressed more strongly in younger and nonthymomatous patients with myasthenia gravis. Surg Today. 2001; 31 11: 1036–1037.
   Google Scholar
• Nauert JB, Klauck TM, Langeberg LK, Scott JD. Gravin, an autoantigen recognized by serum from myasthenia gravis patients, is a kinase scaffold protein. Curr Biol. 1997; 7 1: 52–62.
   Google Scholar
• Grove BD, Bowditch R, Gordon T, del Zoppo G, Ginsberg MH. Restricted endothelial cell expression of gravin in vivo. Anat Rec. 1994; 239 3: 231–242.
   Google Scholar
• Zhou ZH, Zhang Y, Hu YF, Wahl LM, Cisar JO, Notkins AL. The broad antibacterial activity of the natural antibody repertoire is due to polyreactive antibodies. Cell Host Microbe. 2007; 1 1: 51–61.
   Google Scholar
• Baxendale HE, Johnson M, Stephens RC, Yuste J, Klein N, Brown JS, Goldblatt D. Natural human antibodies to pneumococcus have distinctive molecular characteristics and protect against pneumococcal disease. Clin Exp Immunol. 2008; 151 1: 51–60.
   Google Scholar
• Yurasov S, Nussenzweig MC. Regulation of autoreactive antibodies. Curr Opin Rheumatol. 2007; 19 5: 421–426.
   Google Scholar
• Elkon K, Casali P. Nature and functions of autoantibodies. Nat Clin Pract Rheumatol. 2008; 4 9: 491–498.
   PubMedGoogle Scholar
• Lacroix-Desmazes S, Kaveri SV, Mouthon L, Ayouba A, Malanchere E, Coutinho A, Kazatchkine MD. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Meth. 1998; 216 1–2: 117–137.
   PubMed Web of Science ®Google Scholar
• Atassi MZ, Casali P. Molecular mechanisms of autoimmunity. Autoimmunity. 2008; 41 2: 123–132.
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y, Blank M, Abu-Shakra M, Amital H, Barzilai O, Berkun Y, Bizzaro N, Gilburd B, Zandman-Goddard G, Katz U, Krause I, Langevitz P, Mackay IR, Orbach H, Ram M, Sherer Y, Toubi E, Gershwin ME. The mosaic of autoimmunity: Prediction, autoantibodies, and therapy in autoimmune diseases—2008. Isr Med Assoc J. 2008; 10 1: 13–19.
   PubMed Web of Science ®Google Scholar
• Giraud M, Taubert R, Vandiedonck C, Ke X, Levi-Strauss M, Pagani F, Baralle FE, Eymard B, Tranchant C, Gajdos P, Vincent A, Willcox N, Beeson D, Kyewski B, Garchon HJ. An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature. 2007; 448 7156: 934–937.
   Google Scholar
• Fraussen J, Vrolix K, Martinez-Martinez P, Losen M, De Baets MH, Stinissen P, Somers V. B cell characterization and reactivity analysis in multiple sclerosis. Autoimmun Rev. 2009; 8 8: 654–658.
   Google Scholar
• Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, Lanzavecchia A. An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus. Nat Med. 2004; 10 8: 871–875.
   PubMed Web of Science ®Google Scholar
• Alarcon-Segovia D, Ruiz-Arguelles A, Fishbein E. Antibody to nuclear ribonucleoprotein penetrates live human mononuclear cells through Fc receptors. Nature. 1978; 271 5640: 67–69.
   Google Scholar
• Deng SX, Hanson E, Sanz I. In vivo cell penetration and intracellular transport of anti-Sm and anti-La autoantibodies. Int Immunol. 2000; 12 4: 415–423.
   Google Scholar
• Yanase K, Madaio MP. Nuclear localizing anti-DNA antibodies enter cells via caveoli and modulate expression of caveolin and p53. J Autoimmun. 2005; 24 2: 145–151.
   Google Scholar
• Yanase K, Smith RM, Puccetti A, Jarett L, Madaio MP. Receptor-mediated cellular entry of nuclear localizing anti-DNA antibodies via myosin 1. J Clin Invest. 1997; 100 1: 25–31.
   Google Scholar
• Song YC, Sun GH, Lee TP, Huang JC, Yu CL, Chen CH, Tang SJ, Sun KH. Arginines in the CDR of anti-dsDNA autoantibodies facilitate cell internalization via electrostatic interactions. Eur J Immunol. 2008; 38 11: 3178–3190.
   Web of Science ®Google Scholar
• Bartoccioni E, Marino M, Evoli A, Ruegg MA, Scuderi F, Provenzano C. Identification of disease-specific autoantibodies in seronegative myasthenia gravis. Ann NY Acad Sci. 2003; 998:356–358.
   Google Scholar
• Lee JY, Sung JJ, Cho JY, Oh DH, Kim HJ, Park JH, Lee KW, Choi YC, Vincent A. MuSK antibody-positive, seronegative myasthenia gravis in Korea. J Clin Neurosci. 2006; 13 3: 353–355.
   Google Scholar
• Evoli A. Clinical aspects of neuromuscular transmission disorders. Acta Neurol Scand Suppl. 2006; 183:8–11.
   Google Scholar
• Skeie GO, Mygland A, Aarli JA, Gilhus NE. Titin antibodies in patients with late onset myasthenia gravis: Clinical correlations. Autoimmunity. 1995; 20 2: 99–104.
   PubMed Web of Science ®Google Scholar
• Baggi F, Andreetta F, Antozzi C, Simoncini O, Confalonieri P, Labeit S, Cornelio F, Mantegazza R. Anti-titin and antiryanodine receptor antibodies in myasthenia gravis patients with thymoma. Ann NY Acad Sci. 1998; 841:538–541.
   Google Scholar
• Chen XJ, Qiao J, Xiao BG, Lu CZ. The significance of titin antibodies in myasthenia gravis–correlation with thymoma and severity of myasthenia gravis. J Neurol. 2004; 251 8: 1006–1011.
   Google Scholar
• Yamamoto AM, Gajdos P, Eymard B, Tranchant C, Warter JM, Gomez L, Bourquin C, Bach JF, Garchon HJ. Anti-titin antibodies in myasthenia gravis: Tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol. 2001; 58 6: 885–890.
   PubMed Web of Science ®Google Scholar
• Feltkamp TE, van den Berg-Loonen PM, Nijenhuis LE, Engelfriet CP, van Rossum AL, van Loghem JJ, Oosterhuis HJ. Myasthenia gravis, autoantibodies, and HL-A antigens. Br Med J. 1974; 1 5899: 131–133.
   Google Scholar
• Hazama T, Takahashi M, Ueno S, Tarui S. Electrophoretic immunoblotting analysis of anti-thymus microsome antibodies in patients with myasthenia gravis. Acta Neurol Scand. 1989; 79 2: 88–96.
   Google Scholar
• Ohta K, Shigemoto K, Kubo S, Maruyama N, Abe Y, Ueda N, Fujinami A, Ohta M. MuSK Ab described in seropositive MG sera found to be Ab to alkaline phosphatase. Neurology. 2005; 65 12: 1988.
   Google Scholar